Open-Label Extension Study of PRX012 in Subjects with Alzheimer’s Disease Who Were Enrolled in Study PRX012-101 or PRX012-102

2023-503729-20-00 Protocol PRX012-103 Human pharmacology (Phase I) - Other Ended

Start 27 Mar 2024 · End 16 Jan 2026 · Status Ended · 2 EU/EEA countries · 5 sites · Protocol PRX012-103

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 900
Countries 2
Sites 5

Alzheimer’s Disease

Key facts

Sponsor
Othair Prothena Limited
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Nervous System Diseases [C10]
Trial duration
27 Mar 2024 → 16 Jan 2026
Decision date (initial)
2024-01-29
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Alzheimer’s Disease

VersionLevelCodeTermSystem organ class
20.0 LLT 10001896 Alzheimer's disease 10029205

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Othair Prothena Limited

Sponsor organisation
Othair Prothena Limited
Address
Block C, 77 Sir John Rogersons Quay, Grand Canal Docklands 77 Sir John Rogersons Quay Grand Canal Docklands
City
Dublin 2
Postcode
D02 VK60
Country
Ireland

Scientific contact point

Organisation
Othair Prothena Limited
Contact name
Regulatory Affairs

Public contact point

Organisation
Othair Prothena Limited
Contact name
Regulatory Affairs

Locations

2 EU/EEA countries · 5 investigational sites

By country

CountryMS statusPlanned subjectsSites
Poland Ended 20 3
Spain Ended 20 2
Rest of world
United States
860

Investigational sites

Poland

3 sites · Ended
Promente Sp. z o.o.
Promente -Centrum Neurologii i Psychogeriatrii w Bydgoszczy-this is medical entity where is trial, Ul. Teofila Lenartowicza 33/35, 85-133, Bydgoszcz
Neurologia Śląska Centrum Medyczne
Neurologia Śląska Centrum Medyczne, ul. Małachowskiego 51, 40-689, Katowice
Centrum Medyczne Neuromed Sp. z o.o.
Centrum Medyczne Neuromed Sp z o.o, Ul. Jana Biziela 14, 85-163, Bydgoszcz

Spain

2 sites · Ended
Fundacio Ace Institut Catala De Neurociencies Aplicades
Neurology, Gran Via De Carles III 85 Bis, 08028, Barcelona
Hospital Universitari General De Catalunya
Neurology, Calle De Pedro I Pons 1, 08034, Barcelona

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Poland 2024-04-12 2024-04-15 2024-11-20
Spain 2024-03-27 2024-04-15 2024-12-11

Application history

5 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-09-15 Poland Acceptable
2024-01-22
2024-01-29
2 SUBSTANTIAL MODIFICATION SM-2 2024-01-30 Acceptable 2024-02-28
3 SUBSTANTIAL MODIFICATION SM-3 2024-02-01 Poland Acceptable 2024-03-29
4 SUBSTANTIAL MODIFICATION SM-4 2024-07-05 Poland Acceptable
2024-08-19
2024-08-20
5 SUBSTANTIAL MODIFICATION SM-5 2025-06-04 Poland Acceptable
2025-07-21
2025-07-23